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Huntington’s disease (HD) is caused by a dominant polyglutamine expansion within the N-terminus of huntingtin protein and
results in oxidative stress, energetic insufficiency and striatal degeneration. Copper and iron are increased in the striata of HD
patients, but the role of these metals in HD pathogenesis is unknown. We found, using inductively-coupled-plasma mass
spectroscopy, that elevations of copper and iron found in human HD brain are reiterated in the brains of affected HD
transgenic mice. Increased brain copper correlated with decreased levels of the copper export protein, amyloid precursor
protein. We hypothesized that increased amounts of copper bound to low affinity sites could contribute to pro-oxidant
activities and neurodegeneration. We focused on two proteins: huntingtin, because of its centrality to HD, and lactate
dehydrogenase (LDH), because of its documented sensitivity to copper, necessity for normoxic brain energy metabolism and
evidence for altered lactate metabolism in HD brain. The first 171 amino acids of wild-type huntingtin, and its glutamine
expanded mutant form, interacted with copper, but not iron. N171 reduced Cu
2+ in vitro in a 1:1 copper:protein stoichiometry
indicating that this fragment is very redox active. Further, copper promoted and metal chelation inhibited aggregation of cell-
free huntingtin. We found decreased LDH activity, but not protein, and increased lactate levels in HD transgenic mouse brain.
The LDH inhibitor oxamate resulted in neurodegeneration when delivered intra-striatially to healthy mice, indicating that LDH
inhibition is relevant to neurodegeneration in HD. Our findings support a role of pro-oxidant copper-protein interactions in HD
progression and offer a novel target for pharmacotherapeutics.
Citation: Fox JH, Kama JA, Lieberman G, Chopra R, Dorsey K, et al (2007) Mechanisms of Copper Ion Mediated Huntington’s Disease Progression. PLoS
ONE 2(3): e334. doi:10.1371/journal.pone.0000334
INTRODUCTION
Huntington’s disease (HD) is a neurodegenerative disorder
characterized by progressive motor, cognitive and psychiatric
deterioration. HD is caused by a dominant glutamine expansion
within the N-terminus of the huntingtin protein that initiates events
leading to neuronal loss primarily within the striatum and cerebral
cortex. Full-length huntingtin is large (,350 kD), but it is the
smaller N-terminal fragments that are the main mediators of
disease progression [1]. These fragments have aberrant interactions
with themselves and other biomolecules that result in hallmarks of
HD including aggregates [2], transcriptional repression [3],
oxidative injury [4] and mitochondrial dysfunction [5].
Copper and iron concentrations are increased in the striata of
post-mortem human HD brains [6]. Further, ferritin-iron levels
are increased in striata of early clinical HD patients as measured
by MRI [7]. However, the role these metals may have in HD is
unknown. The basal ganglia are sensitive to increased copper and
iron levels. Patients with Wilson’s disease (WD) have large
increases in liver copper. However, 40% of WD cases present
with neurologic symptoms related to copper-mediated striatal
degeneration [8]. Patients with ferritin mutations (neuroferritino-
pathy) accumulate iron and have degeneration in the globus
pallidus [9]. These data suggest possible mechanistic overlap
between HD and disorders of primary basal ganglia copper and
iron accumulation. However, why copper and iron levels increase
in HD and the specific pathways through which they may
potentiate neurodegeneration are unknown.
Accumulation of copper in HD brain could result in interaction
with low affinity binding sites on diverse biomolecules. Aberrant
copper-protein interactions have been implicated in the patho-
genesis of Alzheimer’s, Lou Gehrig’s and Parkinson’s diseases [10–
12]. For polyglutamine diseases, including HD, such interactions
are not reported. However, copper could promote altered mutant
huntingtin conformation, aggregation and/or redox-activity. This
would be analogous to the interaction of beta-amyloid with
copper, which induces beta-amyloid oligomerization thought to
contribute to Alzheimer’s disease pathogenesis [10,13].
Several glycolytic enzymes [14,15] and mitochondrial dehydro-
genases including lactate dehydrogenase (LDH) [15] and succinate
dehydrogenase (SDH) [16,17] are sensitive to copper-mediated
inactivation. LDH is a critical component of the astrocyte-neuron
lactate shuttle whereby lactate released by astrocytes is used as an
energy substrate by neurons [18]. Lactate levels are increased in
human HD striata as measured by magnetic resonance spectroscopy
[19]. Further, a recent study has shown that pre-symptomatic N171-
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PLoS ONE | www.plosone.org 1 March 2007 | Issue 3 | e33482Q HD mice have impaired ability to metabolize lactate, but not
succinate [20]. Taken together, these findings suggest that excess
copper could contribute to HD energetic insufficiency by inhibiting
key enzymes such as LDH.
The major goal of this study was to address the hypothesis that
aberrant copper-protein interactions contribute to HD progression.
We specifically addressed two potential ways in which copper could
contribute to HD pathogenesis, 1.) by modulation of huntingtin
structure, and 2.) by interfering with brain lactate-energy
metabolism, by inhibiting LDH activity. Our findings indicate
that copper could be a hereto unappreciated potentiating factor in
HD that may impact pathogenesis at the level of mutant huntingtin
itself as well as interfering with brain energy metabolism.
MATERIALS AND METHODS
Materials
All reagents were from Sigma unless otherwise stated. Antibodies
used were anti-APLP2 (Calbiochem), anti-ATP7A (Abcam), anti-
ATP7B N-terminus antibody (Novus), anti-APP (MAB348 from
Chemicon; 6E10 from Signet), 1C2 (anti-polyglutamine) (Chemi-
con) and anti-SOD1 (Chemicon). Dr. Marian DiFiglia, and Dr.
Wilma Wasco kindly provided AB1 (detects first 17 amino acids of
huntingtin) and APLP1 antibodies, respectively. HRP-conjugated
secondary antibodies were from Abcam.
N-terminal huntingtin synthesis
A wheat-germ T7-based in-vitro transcription-translation system
was used to generate N-terminal huntingin (Promega). Constructs
used comprised pcDNA1 and expressed the first 171 amino acids of
human huntingtin (N171) containing 17 glutamines, or 68
glutamines. Histidine mutants were generated using QuikChangeH
site-directed mutagenesis kit (Stratagene). To generate purified
N171 huntingtin the above vector inserts were sub-cloned into
BamH1/Not1 sites of pGEX-6P (Amersham). Constructs were
transformed into E.coli strain BL21. Bacteria were grown to
OD600 0.5 at 37uC. Cultures were then treated with 1 mM IPTG
for 3 hours at 37 or 25uC, for wild-type and mutant protein,
respectively.N-171huntingtinfragmentswerepurifiedusingaGST
affinity column and then the GST tag cleaved using PreScission
Protease (Amersham). The exon-1-17Q construct was generated by
introducing a stop codon into the N171 construct using Quik-
ChangeH. For metal reduction assays the N-171-17Q protein was
further purified using a Zebra
TM desalt spin column (Pierce) then
concentrated to ,300 ng/ml using a 9 kDa cut-off iCON
TM
concentrator (Pierce).
Human brain tissue
Control and HD brain tissue were obtained from the Tissue
Resource Center of the Alzheimer Disease Research Center
(ADRC) at Massachusetts General Hospital. Post-mortem inter-
vals were 4 hours.
Immobilized metal affinity chromatography
In-vitro translated samples were diluted 1:1 in binding buffer
(20 mM sodium phosphate, pH 7.2, and 0.5 M NaCl) and applied
to copper charged HiTrap Chelating Sepharose (Amersham)
columns. All dilution, wash and elution solutions contained
a protease inhibitor cocktail lacking EDTA and cysteine modifying
inhibitors (Roche). Unbound protein was washed off using 5 mls of
binding buffer. Bound proteins were then eluted using an
imidazole gradient (8, 16, 32, 64, 128 mM; 1 ml for each fraction)
stepwise in binding buffer. Columns were then stripped using 50
mM EDTA. Protein was precipitated from each fraction using
0.02% (w/v) deoxycholate, 10% (v/v) saturated trichloroacetic
acid incubated overnight at 4uC, followed by centrifugation at
15000 g for 15 minutes. Pellets were then washed in cold acetone,
dried, and then suspended in sample buffer. Samples were
analyzed by Western blotting. For IMAC of brain supernatant,
cortex was homogenized in 30 volumes of binding buffer
containing protease inhibitor then 500 ml of supernatant fraction
was applied directly to the column.
Metal reduction assay
Copper and iron reduction assays were performed using a 96-well
plate format essentially as described [13]. The final reaction
contained 10 mM protein, 20 mM metal ion chloride and 360 mM
bathocuproine or bathophenanthroline disulfonic acid. Protein
concentrations were determined using the DC protein assay (Bio-
Rad) using BSA as a standard.
Huntingtin aggregation assay
Wild-type mouse cortices were homogenized in 30 volumes of
TRIS pH 7.4 containing protease inhibitors lacking EDTA and N-
ethyl maleimide (Roche) then samples clarified by centrifugation at
16000 g. One mg/ml protein with additives (see results) was
incubated at 37uC then samples were resolved on a 5% denaturing
polyacrylamide gel, transferred to PVDF then huntingtin detected
by blotting.
Mice husbandry
All protocols were conducted within NIH guidelines for animal
research and were approved by the Institutional Animal Care and
Use Committee. R6/2 mice express human huntingtin exon-1
containing a glutamine coding CAG. CAG140 knock-in mice have
a CAG expansion within one of the endogenous full-length
huntingtin alleles [21]. Both mouse lines were maintained on the
B6/CBA crossed background. CAG expansion size ranges were
168–190 for R6/2 mice and 116–127 for knock-in mice.
Copper and iron analyses
Mice were deeply anesthetized with ketamine-xylazine then
perfused transcardially for 3 minutes with 0.9% saline prepared
using milli-Q water and containing 25 units/ml heparin. For
figure 1E-F metals were measured by inductively-coupled plasma
(ICP) spectroscopy. Brain samples were digested in 12 mls of nitric
acid: perchloric acid in a 4:1 (v/v) ratio, heated to 250uC on a hot
plate until 1–2 mls of liquid remained. Samples were then cooled
for 5 minutes then diluted to 12 mls using 0.5% nitric acid.
Inductively-coupled-plasma (ICP) spectroscopy was performed as
described [22]. All other metal quantifications in this study were
made by ICP-mass spectroscopy, as described [23]. Buffers for the
brain fractionation study were prepared using milli-Q water,
treated with ChelexH 100 resin (Bio-Rad) to remove residual
metals, then the pH adjusted to 7.2. Saline perfused frontal cortices
were homogenized in five volumes of 10 mM TRIS then
centrifuged at 20000 g for 30 minutes. The soluble fraction was
removed and the pellet re-suspended in the same volume of 10 mM
TRIS containing 1% Triton-X100 then centrifuged at 20000 g for
30 minutes to generate membrane and pellet fractions.
SOD1 assay
Mice were perfused with saline as described above. Brain regions
were homogenizing in 9 volumes of 10 mM HEPES (pH 7.4)
containing a protease inhibitor with EDTA, sonicated briefly and
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of formation of a tetrazolium-formazan dye in the presence of
superoxide (Dojindo Molecular Technologies) using bovine SOD1
as a standard.
LDH and lactate assays
LDH activity was measured by determining the rate of formation of
NAD+ at 340 nm in the presence of pyruvate. For lactate
measurements brain regions were homogenized in 6% perchloric
acid then clarified. The assay was performed in the presence of
50 mM imidazole (pH 7.5), 320 mM glycine, 320 mM hydrazine,
2.4 mM NAD+ and 5.5 u/ml of LDH. Lactate standards were used
to calculate unknown values. In-gel detection of LDH activity was
using a tetrazolium-salt-based chemistry (CytoTox 96H, Promega).
Oxamate infusions
Eight-week-old wild-type mice were anesthetized with a tribro-
moethanol-based agent. Brain cannulas were installed at the
following distances (in mm) from Bregma: 3 deep, 0.2 rostral
and 1.9 left. Micro-osmotic pumps (AlzetH) were calibrated to
delivery 5 nmoles/hour oxamate (pH 7.2). Glucose was used as an
osmolarity control. Mice were sacrificed three days after surgery.
Western blots
Brain regions were homogenized in 9 volumes of 50 mM Tris.HCl
(pH 7.5), 1 mM EDTA and 16HALT protease inhibitor (Pierce
Biotechnology) using a Pellet pestelH (Kontes), sonicated briefly
then centrifuged at 30000 g for 30 minutes at 4uC. Pellets were
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Figure 1. Full-length and N-terminal fragments of human huntingtin interact with copper (II) as measured by immobilized-metal affinity
chromatography (IMAC). A. Full-length (FL) normal and mutant huntingtin from human motor cortex interact with copper and elute with peak
centered at 128 mM imidazole. FL huntingtin has higher affinity for copper (II) than the copper-binding domain of human soluble APLP2. FL protein
migrates at ,350 kDa. B. N-171 fragments of human huntingtin with 17 or 68 glutamines interact with copper (II) and have identical elution profiles.
Proteins with C-terminal FLAG tag elute as a single peak at 32 mM imidazole. Non-FLAG protein elutes primarily at 32 mM imidazole, but also at
higher concentrations. NSB=non-specific band. C. N-171-flag fragments of wild-type and mutant huntingtin do not interact with iron (III). For iron-
IMAC, iron (III) was loaded onto column at pH 3, adjusted to pH 7, then the IMAC procedure performed immediately. D. N-171-17Q fragment (wild-
type) was expressed using the pGEX vector and purified (see methods). Coomassie gel analysis reveals high purity. E. Purified N-171-17Q-flag
fragment of huntingtin interacts directly with copper (II) and elutes identically to the in-vitro transcription-translation expressed protein (Figure 1B).
doi:10.1371/journal.pone.0000334.g001
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NaCl, 0.5% deoxycholate (DOC), 1% SDS, 5 mM EDTA, 1 mM
EGTA and HALT protease inhibitor by pipetting and brief
sonication, then centrifuged at 16000 g for 15 minutes at 4uC.
Primary antibody concentrations were all 1:2000 except for anti-
ATP7B (1:600) and anti-b-actin (1:5000). Secondary antibodies
were all HRP-conjugated and detection used standard procedures.
Quantitative PCR
Total RNA was extracted by homogenization of tissue in Trizol
reagent (Invitrogen) using a Dounce homogenizer. After phase
separation in chloroform, the supernatant fraction was applied
directly to an RNAeasy (Qiagen) column and RNA purified with
on-column DNAase 1 digestion. RNA integrity was confirmed
using an Agilent 2100 Bioanalyzer (LabChip). Reverse transcrip-
tase reactions used 0.5 and 0.8 mg RNA for striatum and cortex,
respectively, and superscript II (Invitrogen). Quantitative PCR was
essentially as described [24]. Primers used (upper/lower) were APP
(5-gaagtcgccgaagaggaggaagtg/5-gttgtggtggtggtggcagtg), APLP1 (5-
cgggagcagcagtgagga/5-ccggaaggagccagttcat), APLP2 (5-agccca-
tagtcagtctgtgttc/5-gcggtggaggtgagtgag). Amplicons were con-
firmed in size and sequence. Relative expression levels for each
target were normalized to b-actin using the 2
2DDT method [25].
Statistical analysis
All data was analyzed using SAS software version 8.2 (SAS, Cary,
NC) using the Students t-test or the generalized-linear-model
procedure for ANOVA. The Dunn-S ˇida ´k method was used to
correct for multiplicity. Mean6standard errors are presented.
RESULTS
Copper interacts directly with N-terminal huntingtin
To address directly whether copper or iron can interact with
huntingtin we used immobilized-metal-affinity chromatography
(IMAC). Firstly, we performed IMAC experiments using cortical
homogenate supernatant fractions from human control and HD
brain. We found that both normal and mutant full-length
huntingtin protein eluted from the copper column using
128 mM imidazole suggesting a fairly strong interaction with
copper (Figure 1A). By comparison soluble amyloid precursor-like
protein 2, a protein with a known copper binding site [26] eluted
at 32–64 mM (Figure 1A) while prion protein (PrP) is known to
elute at 150 mM imidazole [27]. To determine whether
polyglutamine containing N-terminal huntingtin fragments can
interact with copper, we expressed N-terminal fragments of wild-
type and mutant huntingtin by in-vitro transcription-translation
(IVTT) then performed IMAC experiments. Because we were
unable to express mutant exon-1 huntingtin by IVTT we focused
on a longer fragment of N-terminal huntingtin containing the first
171 amino acids of huntingtin with 17 or 68 glutamines (17Q/
68Q), for wild-type and mutant protein respectively. We used
constructs expressing a C-terminal FLAG tag for most of our
experiments. N171-17Q/68Q FLAG fragments both eluted at
32 mM imidazole (Figure 1B). Experiments using N171 fragments
lacking FLAG revealed that N171 also eluted at 32 mM
imidazole, but continued to elute at 64 and 128 mM imidazole
indicating that FLAG attenuates N171-copper interaction
(Figure 1B). Further, the N-171 fragments failed to bind to iron
(III) loaded IMAC columns (Figure 1C). To determine if the N-
171 interaction with copper is direct or depends on another
protein we generated purified N171 using the pGEX bacterial
expression system (Amersham). N171-17Q was pure as measured
by Coomassie staining (Figure 1D). Further, this fragment eluted
identically to the IVTT expressed fragment (Figure 1B and E)
indicating that copper (II) interacts directly with N-171 huntingtin.
Bacterially generated N-171-68Q aggregated on the copper (II)-
IMAC column, however, it partially eluted predominantly in the
32 mM imidazole peak (not shown).
Copper-huntingtin interaction involves histidine
residues
N171 huntingtin protein contains several candidate copper (II)
coordinating residues (Figure 2A). To characterize the nature of an
N-171 huntingtin-copper interaction we determined the pH
dependency of the N171-17Q-copper interaction. Purified N-
171-17Q eluted predominantly in the pH range 4.5–3.5 consistent
with a histidine interaction (Figure 2B). Modification of cysteine
residues on purified N-171-17Q using N-ethyl-maleimide failed to
affect binding (not shown). Mutation of histidines 82 and 98 to
phenylalanine in N-171-68Q protein both resulted in loss of
binding (Figure 2C) indicating that in N171 both residues are
essential for an interaction with copper. However, human exon-1
(17Q) huntingtin (N84), which lacks histidine 98, interacted with
copper (II) and eluted at 32 mM imidazole to EDTA (Figure 2D)
suggesting it has a different conformation and mode of interaction
with copper than N171.
Copper(II) is reduced by and promotes aggregation
of huntingtin
To determine if the copper-N171 complex is redox-active we
determined whether N171 could reduce copper (II) to copper (I).
The experiment was performed using the 17Q protein only because
we were unable to sufficiently purify mutant N171. N171-17Q
reduced copper(II) at a 1:1stoichiometricratio(protein:Cu
2+)within
1 hour (Figure 3A). N171-17Q also reduced iron (III), but to a lesser
extent than copper: approximately 1 mole of Fe
3+ was reduced per 2
moles of protein (Figure 3B). We found that wild-type full-length
huntingtin from mouse brain supernatant fractions formSDS and b-
mercaptoethanol resistant aggregates upon incubation at 37uC
(Figure 3C). Because wild-type huntingtin fragments can aggregate
in-vivo [28] and because polyglutamine length within the normal
range modifies cell phenotype [5] we used wild-type huntingtin to
investigate the effect of chelators and copper on aggregation. We
found thatthe brainpermeable metal chelator clioquinolandEDTA
inhibited formation of aggregates. Aggregation was not blocked by
catalase (indicating that it is not mediated by H2O2), but was
promoted by copper (Figure 3C).
Copper and iron are increased in mouse HD brain
Copper and mutant huntingtin accumulation in HD could increase
the probability of an interaction occurring in brain. To determine if
redox-active metal levels increase with HD progression we measured
copper and iron concentrations in striata and frontal cortices of 12-
month-oldknock-in CAG140and 12-week-oldR6/2transgenicHD
mice. CAG140 mice at 8–18 months had no deficits in open-field
activity (Figure 4A) and brain weights were normal at 12-months
(Figure 4B), consistent with pre-clinical HD. R6/2 mice had open-
field deficits (Figure 4A) and a 12% reduction in brain weight
(Figure 4B) consistent with advanced HD. Despite the absence of
deficits in our CAG140 mice cortical iron levels were significantly
increased 15% (Figure 4D). In R6/2 mice with advanced HD
copper was significantly increased 26% and 51% in striatum and
cortex respectively (Figure 4E). Iron levels were increased in both
regions in the R6/2 brains (Figure 4F), although not reaching
statistical significance in this experiment (see below).
Copper Potentiates HD
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interaction we determined if mutant huntingtin distribution co-
localizes with increases in metal levels in brains of 12-week-old
R6/2 HD mice. We measured cortical metal levels by ICP-MS in
three biochemical fractions and correlated these with mutant
huntingtin protein levels in the same fractions. Metal and
huntingtin measurements were all normalized to wet weight to
allow the distribution of metals and mutant huntingtin to be
compared quantitatively. After correction for multiple testing,
significant increases in copper were present in soluble and
membrane fractions (Figure 5A). Iron levels showed greater
increases in these regions and were also significantly increased in
the pellet fraction (Figure 5B). Zinc concentrations were unaltered
in all fractions (not shown). As expected, we found that R6/2 brain
contains a large excess of mutant huntingtin in insoluble compared
to soluble forms (Figure 5C). Mutant huntingtin was not detected
in the membrane fraction. Neither pellet nor soluble mutant
huntingtin could be detected by Coomassie staining in parallel gels
(not shown). Based on the detection limit of Coomassie blue
(,100 ng) we estimated that at 12-weeks#84 nmoles mutant
huntingtin/g wet weight is present in R6/2 HD cortex. From this
we calculated that in the pellet fraction there is still at least a 17-
fold molar increase of copper over mutant huntingtin. Therefore,
the increase in copper in R6/2 cortex is sufficiently high to be
compatible with binding to all the mutant huntingtin. However, as
the increase in copper is many folds greater than the molar
concentration of mutant huntingtin, significant amounts of excess
copper are available to interact at non-huntingtin sites.
Lactate dehydrogenase activity is decreased in
mouse HD brain and inhibition is sufficient to cause
neurodegeneration
Our data so far suggested that not all the increased copper (and
iron) are in the same biochemical fraction as mutant huntingtin.
We reasoned that this excess copper could be in a toxic form
unassociated with mutant huntingtin. Firstly, we sought evidence
that increased copper could be part of a protective response. As
the R6/2 mouse model of HD mounts a brain anti-oxidant
response to mutant huntingtin [24] we first determined whether
this response includes upregulation of the cuproenzyme SOD1.
However, there was no significant increase in SOD1 activity or
protein levels in striatum or cortex of 12-week R6/2 mice (Figure
S1). To look for evidence of copper toxicity we determined if there
was a reduction in activity of the copper-sensitive enzyme LDH
[15]. LDH activities were decreased in forebrains of affected HD
mice from 8-weeks (Figure 6A). Further, there were no significant
changes in actin-normalized expression levels of LDH monomer
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Figure 2. Interaction of N-171 huntingtin with copper (II) by IMAC involves histidine 82 and 98. A. N171-17Q huntingtin contains several potential
copper (II) coordinating residues, two histidines (red) and four cysteines (blue). The vertical line represents the exon-1-2 boundary. Flag tag sequence
(underlined) partially overlaps with huntingtin sequence (upper case). B. Purified N-171-17Q huntingtin fragment elutes from copper column at pH
4.5–3.5 consistent with interaction with histidine residue(s). Elution solutions were prepared in 20 mM citrate-buffer. C. Modification of histidine 82
and/or 98 to phenylalanine results in elution of protein in washes indicating that both histidines are necessary for interaction with copper (II). D.
Huntingtin exon-1-17Q fragment is sufficient for copper (II) interaction.
doi:10.1371/journal.pone.0000334.g002
Copper Potentiates HD
PLoS ONE | www.plosone.org 5 March 2007 | Issue 3 | e334Reductant 171-17Q 
Met
Phe
His
Ins
Aβ(1-42)
VitC
C
o
p
p
e
r
 
(
I
I
)
 
r
e
d
u
c
e
d
 
(
µ
M
)
 
0
2
4
6
8
10
12
14
16
A
C
   EDTA (μM)   0      0    0    20    0     0     0     0     0     0     
Added copper  (μM)   0      0    0     0     0     0     0     0     0    10  
   Clioquinol  (μM)   0      0   20    0     0     0     0     0     0     0     
Time at 370 C (hours)   0    16  16   16     0    16   16    0     2     2        
   Catalase (μM)   0      0    0     0     0     0    16    0     0     0     
Full-length htt 
(~350 kDa) 
Gell wells
Reductant 171-17Q
Met
Phe
His
Ins
Aβ(1-42)
VitC
I
r
o
n
 
(
I
I
I
)
 
r
e
d
u
c
e
d
 
(
µ
M
)
0
2
4
6
8
10
12
14
16
18
20
B
Figure 3. Copper (II) is reduced by N171-17Q huntingtin and promotes aggregation of cell-free full-length mouse huntingtin. A. N-terminal huntingtin (N-
171-17Q) reduces copper (II) as measured by the bathocuproine assay. B. Iron (III) is reduced by N171-17Q to a lesser extent than copper as measured by
bathophenanthroline assay. Met=methionine, Phe=phenylalanine, His=histidine, Ins=insulin, VitC=ascorbate. Purified N171-17Q proteins were
incubatedfor1 hourat37uCinthepresenceof20 mM of copper (II) or iron (III) and 360 mMbathocuproineorbathophenanthrolineforcopper(II)andiron
(III) reduction assays, respectively. n=4. C. Full-length wild-type mouse huntingtin aggregates following incubation at 37uC. Aggregation is promoted by
10 mM copper (II) and inhibited by EDTA and the brain permeable chelator, clioquinol. Aggregation is not inhibited by co-incubation with catalase.
doi:10.1371/journal.pone.0000334.g003
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PLoS ONE | www.plosone.org 6 March 2007 | Issue 3 | e334protein as measured by Western blotting (Figure 6B) indicating
that reduced LDH activity is not the result of decreased protein
levels in the R6/2 mouse. All five LDH isoenzymes had decreased
activities in 12-week R6/2 HD mice (Figure 6B). Averaging across
the five LDH isoenzymes there was a 55% decrease in actin-
normalized activity (p=0.0421) which is comparable to the
enzymatic activity data. Further, at the same age we found
increased L-lactate levels in R6/2 striatum and cortex (Figure 6C).
We investigated the sensitivity of LDH to copper and other metals.
LDH was inhibited.95% after 1 hour incubation in 5 mM copper
(II) but there was no effect of manganese (II) or iron (III) at up to
80 mM (Figure 6D). These findings are consistent with copper
inhibiting LDH in brain, resulting in altered brain L-lactate
metabolism. To determine whether LDH inhibition in brain can
contribute to neurodegeneration we infused the LDH inhibitor,
oxamate, into the striatum of wild-type mice. After three days
there was significant striatal degeneration in oxamate treated, but
not control mice (Figure 6E).
Decreased expression of the copper export protein
APP in HD brain
To characterize further the state of copper homeostasis in R6/2
mice we analyzed the expression of several copper homeostatic
proteins. We analyzed amyloid precursor protein (APP) and APP-
like protein 2 (APLP2) because mice lacking these proteins have
increased brain and liver copper levels [29]. Because APP family
proteins are cleaved within their single transmembrane region to
yield an N-terminal extracellular soluble form we measured APP
and APLP2 protein levels in soluble and membrane fractions. Both
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PLoS ONE | www.plosone.org 7 March 2007 | Issue 3 | e334forms of APP were highly significantly decreased (,45%) in
striatum and cortex of 12-week-old R6/2 mice (Figure 7A–D).
APLP2 was decreased in the soluble fraction of striatum only and
APLP1 levels were unaltered. APP, APLP2 and APLP1 mRNA
transcript levels were unaltered (Figure 7E–G). The copper-
transporting ATPase, Wilson’s disease protein (ATP7B) was
increased 40% in cortex, but not in striatum (Figure 7H). There
were no significant changes in copper-transporting Menke’s
disease protein (ATP7A) expression (Figure 7H).
DISCUSSION
Accumulation of basal ganglia copper or iron results in
neurodegeneration [30,31]. In this study, we tested the hypothesis
that in HD brain copper accumulates and promotes disease
progression by pro-oxidant protein interactions. We focused on
two proteins: huntingtin, because of its centrality to HD [32], and
lactate dehydrogenase (LDH) because of its documented sensitivity
to copper [15], necessity for normoxic brain energy metabolism
[18] and evidence for altered lactate metabolism in HD brain [19].
We tested this hypothesis in experiments using post-mortem brain
tissue from HD patients, human huntingtin fragments expressed
biochemically and in transgenic mice, and using a knock-in model
of HD expressing full-length mutant huntingtin. Our findings
support the role of excess copper as a potentiating factor in HD.
We used immobilized metal affinity chromatography (IMAC) to
investigate whether huntingtin interacts with copper. IMAC has
previously been used to investigate copper-protein interactions
involved in neurodegenerative disease [26]. Experiments revealed
that N171 containing a normal (17Q) or expanded (68Q)
glutamine tract interacted with copper (II), but not iron (III) or
zinc (not shown). We identified histidines 82 and 98 as both
essential for copper interaction (Figure 2B–C) suggesting that they
coordinate a single copper ion. The exon-1-17Q fragment (N84)
also interacted with copper (II) (Figure 2D) indicating that our
findings of a copper-N-terminal huntingtin interaction are relevant
to the neurodegenerative phenotype of the R6/2 HD mouse
which expresses exon-1 of mutant huntingtin. However, as the
N171 fragment with the H98F mutation did not bind to the IMAC
column it suggests that exon-1 and N171 fragments coordinate
copper differently (see Figure 2A). We have no direct evidence that
glutamine expansion affects copper-binding. However, sequences
flanking the polyglutamine tract have profound influences on
huntingtin toxicity [33], therefore, our findings are consistent with
a process that could modulate huntingtin toxicity in-vivo.
We found that N171-17Q protein is a strong reducer of copper
(II) indicating that copper (II) and N171-17Q huntingtin not only
interact in solution but that an interaction can result in electron
transfer. The overall level of copper reduction by N171-17Q was
much greater than insulin, a protein oxidized by copper [34], and
similar to that reported for Abeta(1–42) [13] indicating that N171
protein is very redox active. Iron (III) reduction by N171-17Q did
occur, but was much less than copper (II) (Figure 3A–B). This
suggests that iron may interact with N-terminal huntingtin in
solution even though an interaction was not detected by IMAC.
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centers of reactive oxygen species (ROS) production in cultured
cells [35]. The authors implicated iron in this process because
ROS production was inhibited when the metal chelator
deferoxamine was added to cell culture medium, even though
deferoxamine is not specific for iron. Despite this interpretation,
these results are in general agreement with each other indicating
that N-terminal huntingtin redox activity may be important in HD
pathogenesis.
Insoluble huntingtin aggregates are one pathologic hallmark of
HD [2]. Our finding that copper promotes and metal chelation
inhibits cell-free formation of SDS and b-mercaptoethanol
resistant huntingtin aggregates (Figure 3C) suggests that copper
could modulate mutant huntingtin aggregation in-vivo. These
findings raise the possibility that metal chelators could be
neuroprotective in HD by inhibiting early structural changes
and silencing redox activity of mutant huntingtin. The brain
permeable copper and iron chelator clioquinol is neuroprotective
and decreases brain aggregate load in R6/2 HD mice [36].
Further, epigallocatechin-gallate, a green tea flavonoid and copper
chelator [37] modulates early events in huntingtin misfolding and
reduces toxicity in a Drosophila model of HD [38]. While the role
of microscopically visible aggregates in HD pathogenesis is
controversial, our findings indicate that copper interacts with
mutant N-terminal huntingtin monomers (Figure 1). This indicates
that copper may modulate aggregation by influencing proximal
mutant huntingtin structural changes in the cascade from mono-
mer to oligomer and microscopic aggregate. The exact mechanism
by which this occurs is unclear. Possibilities include copper-
mediated conformational change, huntingtin oxidation, and
proteolysis.
Copper and iron levels were significantly increased in brains of
12-week R6/2 HD mice, corresponding to late-stage HD.
However, only iron was increased in the brains of 12-month
CAG140 HD mice, corresponding to pre-clinical HD (Figures 4A–
D). The effects in R6/2 mice are unlikely to be due to shifts in cell
populations with advancing HD because cortical zinc concentra-
tions were unaltered (not shown). Our findings demonstrate that
these models may be useful for understanding the altered copper
and iron homeostasis that occurs in human HD [6]. They also
argue for an early role of iron in HD. Further, because we did not
detect increases in copper in CAG140 mice with pre-clinical
disease our results are most consistent with copper potentiating
HD progression, rather than acting very early in disease
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mice) and copper (R6/2 mice), rather than striatum, is consistent
with HD mechanisms in which cortical dysfunction results in
striatal degeneration [39,40].
To address whether the distributions of increased copper and
mutant huntingtin in different biochemical fractions are compat-
ible with an interaction occurring in brain we correlated their
distributions in R6/2 cortex. We also measured iron because an
interaction with aggregated huntingtin cannot be excluded based
on our biochemical findings. We found significant increases in
copper and iron in specific fractions (Figure 4A–B). The molar
increase in copper and iron was several times greater than the
amount of mutant exon-1 huntingtin present (see results).
Therefore, our data suggest that not all the increased copper
can be bound to mutant huntingtin if there is a 1:1 binding
stoichiometry and that some excess metals are likely at other
cellular or sub-cellular sites where they may be mediating
oxidative injury.
Copper inactivates LDH by direct oxidation of an active-site
cysteine residue [15]. In our studies, forebrains of 12-week-old
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levels suggesting that disturbances in lactate metabolism could be
directly due to reduced LDH activity. It has recently been shown
that LDH-B isoform mRNA levels are decreased in N171-82Q
mice and human HD brain due to decreased signaling through the
PPARc coactivator 1a (PGC-1a) pathway [20]. Further, N171-
82Q mice have decreased ability to utilize lactate as an energy
substrate [20]. While defects in PGC-1a signaling are also present
in R6/2 HD mice [41] we did not detect decreases in total LDH
monomer protein levels as measured by Western blotting
(Figure 6B). Despite unaltered LDH monomer levels, both our
biochemical and in-gel LDH activity assays demonstrate an age-
dependent decline of LDH activity in R6/2 HD brain (Figure 6A-
B). Given the increased forebrain copper in R6/2 mice at 12-
weeks (Figure 4E) and the sensitivity of LDH to copper-mediated
inactivation (Figure 6D) we suggest that reduced LDH activity is,
at least in part, the result of copper-mediated enzymatic inhibition.
This interpretation is supported by our fractionation studies
suggesting that increased copper is not entirely associated with
mutant huntingtin. The LDH inhibitor oxamate resulted in striatal
degeneration (Figure 6E) indicating that a defect in LDH activity is
sufficient to contribute to neurodegeneration in HD mice. Taken
together, these data suggest that copper interferes with lactate
metabolism in HD brain by inhibiting LDH.
Copper levels could increase in HD brain for a number of
reasons including increased expression of neuroprotective cupro-
proteins, altered expression of copper-homeostatic proteins and
accumulation of mutant huntingtin containing a copper-binding
site. Liver copper (and iron) levels were unaltered in R6/2 mice at
12-weeks ruling out systemic accumulation as a factor (not shown).
R6/2 HD mice mount a compensatory anti-oxidant response [24].
Further, SOD1 is an important anti-oxidant and represents about
1% of total brain protein; however, we did not detect significant
shifts in protein or activity levels that might explain increased
copper levels in R6/2 mice (Figure S1). We analyzed levels of
several proteins implicated in copper homeostasis. APP and
APLP2 knock-out mice have increased cortical copper concentra-
tions [29]. We found that R6/2 HD mice had decreased levels of
APP and APLP2 (Figure 7A-D) suggesting that this could be one
factor explaining increased copper. Similar to R6/2 mice, APP
knock-out mice have decreased grip strength and locomotor
activity [42]. APP and APLP2 transcript levels were unaltered in
R6/2 mice and we did not detect degradation products by
Western blotting suggesting that decreased levels of these proteins
may result from translational inhibition. In addition to its role in
copper-export APP has neuroprotective [43] and neurotrophic
effects [44,45]. Therefore, decreased APP levels in R6/2 HD mice
could contribute to neurodegeneration by copper-dependent and
independent mechanisms.
We have provided evidence that copper interactions with
mutant huntingtin and LDH are important in HD pathogenesis.
While the interaction of N-terminal huntingtin with copper is
a new finding, redox-mediated mechanisms of mutant huntingtin
toxicity are compatible with established mechanisms of huntingtin
toxicity such as dysregulation of axonal transport and transcrip-
tion. In addition to the mechanisms proposed, copper could
promote HD progression in additional ways. For example, in the
presence of hydrogen peroxide, ions of copper are highly reactive
towards DNA, several fold more reactive than iron [46,47] and
there is evidence for abundant DNA oxidation in HD brain [4,48].
Further, the neurotoxic metabolite 3-hydroxykynurenine is in-
creased in HD [49,50] and in-vitro reacts more readily with
copper than iron to generate hydrogen peroxide [51]. Despite the
proposed importance of copper, iron may play an important and
early role in HD, and this requires more investigation. More work
is also needed to further quantify affinities and specificities of metal
ion binding to N-terminal huntingtin fragments and to better
understand the redox chemistry involved. When taken together
however, our findings underscore the relevance of metal-protein
chemistries in HD brain and suggest neuroprotective stratagies.
SUPPORTING INFORMATION
Figure S1 SOD1 protein and activity levels in striatum and
cortex of HD mice. A. SOD1 protein levels are unaltered in cortex
and striatum of HD mice. B. SOD1 activity is unaltered in
striatum and non-significantly increased in cortex (p=0.0962). All
measurements were at 12-weeks of age. n=10, black bars=wild-
type, cross-hatched=HD transgenic.
Found at: doi:10.1371/journal.pone.0000334.s001 (0.62 MB EPS)
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